| Project/Area Number |
21592128
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Ehime University (2011)
Nagoya University (2009-2010) |
|---|
Principal Investigator |
NAWA Akihiro 愛媛大学, 大学院・医学系研究科, 教授 (90242859)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KIKKAWA Fumitaka 名古屋大学, 大学院医学系研究科, 教授 (40224985)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | がん幹細胞 / CD133陽性細胞 / OATP8遺伝子 / タキソール / 薬剤耐性 / OATP8 / Taxol / realtime RT-PCR / h-TERT-promoter / Lenti virus vector / OATP8siRNA / oncolytic virotherapy / ovarian cancer / carrier cell / dissemination / herpes simplex virus / cell-to-cell / intraperitoneal therapy |
|---|
| Research Abstract |
We have developed replication-competent, attenuated herpes simplex virus-1(HSV-1) mutants, which have been evaluated for their oncolytic activities. However, the host immune system remains a significant obstacle to effective intraperitoneal administration of these viruses in the clinical setting. In this study, we investigated the use of these HSV-1 mutants as oncolytic agents against ovarian cancer and human peritoneal mesothelial cells as carrier cells for intraperitoneal therapy. Our results indicate that these HSV-1 mutants exerts a potent oncolytic effect on ovarian cancer, which may be further enhanced by the utilization of a carrier cell delivery system, based on amplification of viral load and possibly on avoidance of neutralizing antibodies.
|
